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Abstract
Background: The strong anti-oxidative properties of bilirubin largely explain its cardioprotective effects. Insulin resistance is
featured by low circulating bilirubin. Thyroid hormone affects both bilirubin generation and its biliary transport, but it is
unknown whether circulating bilirubin is associated with thyroid function in euthyroid subjects. Aim is to determine
relationships of bilirubin with TSH, free T4 and free T3 in euthyroid subjects without type 2 diabetes mellitus (T2DM), and to
assess whether such a relationship would be modified by the degree of insulin resistance.
Methods: Total bilirubin, TSH, free T4, free T3, glucose, insulin, lipids and transaminases were measured in 1854 fasting
euthyroid subjects without T2DM, recruited from the general population (PREVEND cohort). Insulin resistance was assessed
by homeostasis model assessment.
Results: Bilirubin was positively related to free T4 (b= 0.116, P,0.001) and free T3 (b= 0.078, P= 0.001), but bilirubin was
unrelated to TSH. The relationship of bilirubin with free T4 was modified by insulin resistance with a larger effect in more
insulin resistant individuals (adjusted for age and sex: b= 0.043, P= 0.056 for interaction; additionally adjusted for smoking,
alcohol intake, transaminases and total cholesterol (b= 0.044, P= 0.044 for interaction). The association of bilirubin with free
T4 was also modified by high density lipoprotein cholesterol (age- and sex-adjusted: b= 0.040, P= 0.072).
Conclusions: Low bilirubin relates to low free T4 in euthyroid non-diabetic subjects. Low normal free T4 may particularly
confer low bilirubin in more insulin resistant individuals.
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Introduction
It is increasingly appreciated that endogenous bilirubin has
strong anti-oxidative properties, which are attributed to its ability
to scavenge peroxyl radicals and to inhibit low density
lipoprotein (LDL) oxidation [1]. Hence, the concept is emerging
that bilirubin is involved in the pathogenesis of cardiometabolic
disorders in which oxidative-stress is considered to play an
important role [1–3]. In this line, low circulating levels of
bilirubin levels have been documented to be associated with
increased severity of atherosclerosis [4] and higher risk of lower
limb amputation [5]. Low levels of circulating bilirubin have also
been associated with increased cardiovascular and all-cause
mortality in men [6]. In addition, intima media thickness, an
established marker of subclinical atherosclerosis, is smaller in
subjects with isolated hyperbilirubinemia [7]. Conversely,
increased intima media thickness relates to low bilirubin in
middle-aged subjects [8].
The importance of bilirubin for the development of athero-
sclerotic cardiovascular diseases underscores the relevance to
delineate the metabolic factors that affect its metabolism in more
detail. Thyroid hormones stimulate heme oxygenase-1 activity
(HO-1), which is the main enzyme responsible for bilirubin
production [9,10]. Furthermore, thyroid hormones downregulate
the enzymatic activity of uridine 59-diphospho-glucuronosyltrans-
ferase (UDP-GT), which stimulates bilirubin conjugation, thereby
facilitating bilirubin excretion [11,12]. In agreement with the
hypothesis that thyroid function represents a clinically relevant
determinant of serum bilirubin metabolism, we have recently
shown that low free T4 levels confer decreased bilirubin levels in
euthyroid patients with type 2 diabetes mellitus (T2DM) [13]. Of
further interest, insulin resistance and the metabolic syndrome
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(MetS) are not only featured by low bilirubin levels, but also by
low free T4 [14,15]. In extension thereof, it may be hypothesized
that a possible relationship of bilirubin with thyroid function
among euthyroid subjects is influenced by insulin resistance.
Against this background, the present study was initiated to test
whether low plasma bilirubin is related to a lower thyroid
functional status in euthyroid non-diabetic subjects recruited from
the general population. Second, we determined the extent to
which such a relationship is modified by the degree of insulin
resistance and MetS components.
Methods
Subjects
The population used for this study consisted of a random subset
of participants of the PREVEND (Prevention of Renal and
Vascular End Stage Disease) study, which are inhabitants, aged
28–75 yr, of the city of Groningen, The Netherlands. The
protocol of this study has been described elsewhere [16,17]. The
medical ethics committee of the University Medical Center
Groningen approved the study, and all participants gave written
informed consent. A health questionnaire indicated that the
participants had no history of liver disease.
For the current analysis, we excluded subjects not being
euthyroid, subjects using thyroid hormones, anti-thyroid drugs
and amiodarone, subjects with diabetes mellitus (as indicated by
self-reported questionnaire, a physician diagnosis of diabetes, the
use of oral glucose-lowering medication and/or elevated plasma
glucose), as well as subjects in whom blood was not taken in the
fasting state. Euthyroidism was defined as TSH, free T4 and free
T3 levels within the reference range as provided by the
manufacturer (see Laboratory analyses). We additionally exclud-
ed subjects with positive anti-thyroid peroxidase auto-antibodies
(cut-off value: see Laboratory analyses). Applying these selection
criteria, 1854 subjects were eligible for the current analyses.
Patient characteristics, including age, sex, alcohol use, smoking
status, body mass index (BMI), systolic and diastolic blood
pressure, and waist circumference were obtained. Blood was
drawn after an overnight fasting period for measurement of free
T4, free T3, TSH, bilirubin, glucose, insulin, total cholesterol, high
density lipoprotein (HDL) cholesterol, triglycerides, aspartate
aminotransferase (AST), and alanine aminotransferase (ALT).
Table 1. Clinical characteristics, glucose, insulin, insulin resistance, lipids, transaminases, and thyroid hormones in 1854 subjects.
Sex-stratified tertiles of bilirubin
1 2 3
Men (n = 335) Men (n = 324) Men (n = 263)
,7 mmol/L 7–9 mmol/L .9 mmol/L
Women (n = 354) Women (n = 274) Women (n = 291)
,6 mmol/L 6–7 mmol/L .7 mmol/L b P-value
Age (years) 48612 48613 46613 20.037 0.109
BMI (kg/m2) 26.564.5 25.764.4 25.163.9 20.114 ,0.001
Alcohol 0.077 0.001
,10 gram per day (%) 76 69 72
$10 gram per day (%) 24 31 28
Current smoker (%) 44 36 27 20.163 ,0.001
Waist circumference in men (cm) 95612 92611 92612 20.109 0.001
Waist circumference in women (cm) 83613 82613 80611 20.125 ,0.001
Systolic blood pressure (mmHg) 129621 129619 126620 0.022 0.338
Diastolic blood pressure (mmHg) 7469 7469 73610 0.012 0.595
Glucose (mmol/L) 4.4 (4.0–4.9) 4.4 (4.0–4.8) 4.2 (3.9–4.6) 20.028 0.234
Insulin (mU/L) 9.0 (6.1–13.2) 7.6 (5.5–11.1) 7.1 (5.1–10.0) 20.133 ,0.001
HOMA-IR 1.74 (1.15–2.76) 1.47 (1.03–2.26) 1.33 (0.92–1.94) 20.122 ,0.001
Total cholesterol (mmol/L) 5.8261.16 5.6061.16 5.4161.08 20.113 ,0.001
HDL cholesterol (mmol/L) 1.3260.39 1.3560.39 1.4360.43 0.031 0.189
Triglycerides (mmol/L) 1.24 (0.89–1.87) 1.12 (0.84–1.56) 1.01 (0.74–1.43) 20.121 ,0.001
Metabolic syndrome (%) 25 17 13 20.101 0.001
TSH (mU/L) 1.34 (0.98–1.87) 1.28 (0.94–1.82) 1.37 (1.00–1.85) 20.033 0.152
Free T4 (pmol/L) 12.6661.69 13.0861.79 13.0461.77 0.116 ,0.001
Free T3 (pmol/L) 3.6960.62 3.7260.61 3.8060.62 0.078 0.001
AST (U/L) 24 (21–28) 24 (21–29) 25 (21–29) 0.154 ,0.001
ALT (U/L) 20 (15–28) 20 (16–28) 20 (15–29) 0.115 ,0.001
Data in mean6 SD or in median (interquartile range). BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; HDL, high density lipoprotein;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; b, standardized regression coefficient. P-values for linear trend are shown. Bilirubin, glucose, insulin,
HOMA-IR, triglycerides, TSH, AST and ALT were log transformed.
doi:10.1371/journal.pone.0090886.t001
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Body mass index was defined as weight (kg) by height (m)
squared. Alcohol consumption was recorded with one drink
being assumed to contain 10 grams of alcohol. Insulin resistance
was estimated using the Homeostasis Model Assessment-Insulin
Resistance (HOMA-IR): glucose (mmol/L) 6 insulin (mU/L)/
22.5 [18]. Three or more of the following criteria were required
for categorization of subjects with MetS: waist circumference .
102 cm for men and .88 cm for women, hypertension (blood
pressure $130/85 mmHg or use of anti-hypertensive drugs),
fasting triglycerides $1.70 mmol/L, fasting glucose $5.6 mmol/
L, and HDL cholesterol ,1.03 mmol/L for men and ,
1.29 mmol/L for women [19].
Laboratory analyses
Heparinized plasma and serum samples were stored at 280uC
until analyses. Serum TSH (Architect; Abbott Laboratories,
Abbott Park, IL, USA; reference range 0.35–4.94 mU/L), free
T4 (AxSYM; Abbott Laboratories, Abbott Park, IL, USA;
reference range 9.14–23.81 pmol/L) and free T3 (AxSYM;
Abbott Laboratories, Abbott Park, IL, USA; reference range;
2.23–5.35 pmol/L) were measured by microparticle enzyme
immunoassay. Anti-thyroid peroxidase autoantibodies were
determined using commercially available automated enzyme
linked immunoassays (Abbott Laboratories, Abbott Park, IL,
USA; kit number 5F57). Anti-thyroid peroxidase autoantibodies
were considered positive using a cutoff value as indicated by the
supplier ($12 kU/L). Plasma total bilirubin was measured by a
colorimetric assay (2,4-dicholoraniline reaction; Merck MEGA,
Darmstadt, Germany). In healthy subjects, bilirubin is most
abundantly present in serum in its unconjugated form [20]. In a
validation experiment (n = 80), a strong correlation between total
bilirubin and unconjugated bilirubin (Spearman’s r = 0.92, P,
0.001), as well as between total bilirubin and conjugated direct
bilirubin (Spearman’s r = 0.82, P,0.001) was observed. For the
present study we only used total bilirubin in keeping with other
reports [21–23]. Serum ALT and AST were measured with
pyridoxal phosphate activation (Merck MEGA, Darmstadt,
Germany). Serum total cholesterol and plasma glucose were
measured using Kodak Ektachem dry chemistry (Eastman
Kodak, Rochester, NY, USA). Serum triglycerides were mea-
sured enzymatically. HDL cholesterol was measured with a
homogeneous method (direct HDL, AEROSET system; Abbott
Laboratories, Abbott Park, IL, USA; no. 7D67). Insulin was
measured by microparticle enzyme immunoassay (AxSYM;
Abbott Laboratories, Abbott Park, IL, USA).
Statistical analyses
Data analyses were performed using SPSS (version 20.0, SPSS
Inc. Chicago, IL, USA). Normally distributed data are given as
mean 6 standard deviation (SD) and non-parametrically
distributed data are presented as median (interquartile range,
IQR). Categorical variables are given as percentages. Differences
in bilirubin concentration between sexes were determined by
Mann-Whitney U-test. Characteristics of the study population
are presented according to sex-stratified tertiles of bilirubin.
Univariable linear regression analysis was used to test for linear
trends across tertiles of bilirubin. Multivariable linear regression
analyses were used to determine the extent to which bilirubin is
related to thyroid function, components of the metabolic
syndrome, insulin, HOMA-IR and transaminases. To this end,
logarithmically transformed values of bilirubin, glucose, insulin,
HOMA-IR, triglycerides, TSH and transaminases were used.
Multivariable models were all age- and sex-adjusted. Before
calculating interaction terms, the continuous variable of interest
were centered to the mean by subtracting the group mean value
from individual values. This was done in order to avoid
multicollinearity [24,25]. Interaction terms were considered
statistically significant at P-values ,0.10, as proposed by Selvin
[26] and recommended by the Food and Drug Administration
authorities [27]. Otherwise, two-sided P-values ,0.05 were
considered significant.
Results
A total of 1854 subjects (age 47613, 50% men) participated in
this study. Median bilirubin concentration was 8 (6–10) mmol/L in
men and 6 (5–8) mmol/L in women (P,0.001). Clinical and
laboratory characteristics of the study population are, therefore,
shown according to sex-stratified tertiles of bilirubin (Table 1).
Angiotensin converting enzyme inhibitors (ACEi) or angiotensin
receptor blockers (ARB’s) were used by 56 subjects (3%); 46
subjects (3%) used lipid lowering drugs (mainly statins).
In univariable analyses, bilirubin was inversely related to age,
BMI, smoking status, waist circumference, insulin, HOMA-IR,
total cholesterol, triglycerides, and the presence of metabolic
syndrome (Table 1). We also found positive relationships of
bilirubin with free T4 and free T3, alcohol use, ALT, and AST.
Bilirubin was not associated with blood pressure, glucose, HDL
cholesterol and TSH. There were no interactions of sex with free
T4, free T3 and TSH on bilirubin (P.0.29 for all; data not
shown). In age- and sex-adjusted linear regression analyses
(Table 2), bilirubin was positively associated with free T4, but
there were no significant associations of bilirubin with free T3
and TSH. Bilirubin was inversely associated with diastolic blood
pressure, waist circumference, glucose, insulin, HOMA-IR, total
cholesterol, HDL cholesterol and triglycerides in age- and sex-
adjusted analyses (Table 2).
We then tested whether the relationship of bilirubin with free
T4 was modified by HOMA-IR, fasting insulin, individual MetS
Table 2. Age- and sex-adjusted linear regression analyses
demonstrating relationships of bilirubin with thyroid
hormones, components of the metabolic syndrome, insulin,
insulin resistance and total cholesterol.
Total bilirubin (mmol/L)
b P-value
TSH (mU/L) 20.015 0.510
Free T4 (pmol/L) 0.086 ,0.001
Free T3 (pmol/L) 0.033 0.150
Systolic blood pressure (mmHg) 20.028 0.296
Diastolic blood pressure (mmHg) 20.058 0.026
Waist circumference (cm) 20.116 ,0.001
Glucose (mmol/L) 20.055 0.022
Insulin (mU/L) 20.144 ,0.001
HOMA-IR 20.143 ,0.001
Total cholesterol (mmol/L) 20.121 ,0.001
HDL cholesterol (mmol/L) 0.154 ,0.001
Triglycerides (mmol/L) 20.176 ,0.001
HDL, high density lipoprotein; HOMA-IR, homeostasis model assessment-insulin
resistance; b, standardized regression coefficient. Bilirubin, TSH, glucose, insulin
and HOMA-IR and triglycerides were log transformed.
doi:10.1371/journal.pone.0090886.t002
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components, and total cholesterol. The relationship of bilirubin
with free T4 was significantly modified by HOMA-IR (b=0.043,
P=0.056 for interaction; Table 3) and by plasma insulin
(b=0.040, P=0.072 for interaction; Table S1). The effect-
modification of free T4 by HOMA-IR was independent of
potential confounding factors including smoking, alcohol use $
10 gram/day, AST, ALT and total cholesterol (b=0.044,
P=0.044 for interaction; Table 3). Figure 1 provides a graphical
presentation of the modification of the effect of free T4 on
bilirubin by HOMA-IR. As shown in Table S1, there were no
significant modifications of the effect of free T4 on bilirubin by
systolic blood pressure, diastolic blood pressure, waist circumfer-
ence, glucose, total cholesterol, or triglycerides in age- and sex-
adjusted analyses (P.0.27 for all), but there was a significant
modification of the effect of free T4 on bilirubin by HDL
cholesterol (b=0.040, P=0.072). In addition, there were no
significant modifications of a potential effect of free T3 on
bilirubin by HOMA-IR, fasting insulin, components of the
metabolic syndrome, and total cholesterol (P.0.32 for all; data
not shown).
Secondary analyses were performed after exclusion of subjects
using lipid lowering drugs, ACEi and ARB’s. In the remaining
subjects (n = 1759), there was again an age- and sex-adjusted
positive relationship of bilirubin with free T4 (b=0.094, P,
0.001). Furthermore, the interaction of free T4 with HOMA-IR
on bilirubin was also significant in these analyses (b=0.050,
P=0.030 for interaction), and remained significant after further
adjustment for alcohol intake, transaminases and total cholesterol
(b=0.056, P=0.013 for interaction).
Discussion
To our knowledge, this is the first report on an independent
positive relationship of total bilirubin with free T4 in a large group
of euthyroid, non-diabetic individuals recruited from the general
population. Of note, multivariable linear regression analyses
demonstrated a significant positive modification of the effect of
free T4 on bilirubin by insulin resistance as quantified by HOMA-
IR. This effect-modification remained essentially unaltered after
controlling for potential confounders, including smoking, alcohol,
transaminases, and total cholesterol. Our results, therefore, are in
concert with the hypothesis that low-normal thyroid function may
confer lower circulating bilirubin levels, especially in insulin
resistant individuals. In addition, the effect of free T4 on bilirubin
was modified by the HDL cholesterol concentration.
We recently documented a positive relationship of circulating
levels of bilirubin with free T4 in euthyroid T2DM subjects [13].
In that report, bilirubin was not significantly correlated with free
Figure 1. Graphical presentation of the interaction of free T4 with insulin resistance on bilirubin. The standardized regression
coefficients of the interaction term obtained by multivariable linear regression analysis as shown in Table 3, model 3 is used.
doi:10.1371/journal.pone.0090886.g001
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T4 in non-diabetic subjects, possibly due to the limited number of
participants. Moreover, it could not be determined what was the
driving force behind this association, i.e. insulin resistance or
hyperglycemia resulting from b-cell dysfunction. Our previous
findings [13], therefore, endorsed our main rationale to investigate
the association between bilirubin and free T4 in a large group of
non-diabetic subjects. In the current study, we found bilirubin to
be more strongly associated with HOMA-IR and insulin than with
glucose in age- and sex-adjusted analysis. Furthermore, a positive
modification of the effect of free T4 on bilirubin by HOMA-IR
was observed in such a way that the effect of free T4 on bilirubin
was most pronounced in the most insulin resistant subjects. This
effect modification was not observed with plasma glucose, raising
the possibility that insulin resistance rather than hyperglycemia per
se could represent a mechanism linking low bilirubin to low normal
thyroid function. In view of the strong anti-oxidative properties of
the HDL fraction [28], and the modification of HDL anti-
oxidative capacity by thyroid function [29], it is also of potential
relevance that the effect of free T4 on bilirubin was modified by
HDL cholesterol.
The interaction of free T4 with insulin resistance on bilirubin
may have pathophysiological relevance since lower thyroid
functional status, impaired insulin sensitivity, and low bilirubin
are all characterized by enhanced oxidative stress [2,30–32]. The
positive relationship of bilirubin with free T4 may at least in part
be explained by effects of thyroid function on bilirubin production,
given the stimulatory effect of thyroid hormone on HO-1
expression, and the inhibitory effect on UDP-glucuronosyltrans-
ferase [10–12]. HO-1 expression is stimulated by insulin in vitro
[33,34]. Furthermore, plasma levels of HO-1 are elevated in
subjects with pre-diabetes and are strongly correlated with
HOMA-IR [35]. Taken these findings together, it is plausible to
hypothesize that effects of thyroid hormone on HO-1 expression
could be more prominent in hyperinsulinemic and more insulin
resistant individuals. On the other hand, it is obvious that
stimulatory effects of insulin on HO-1 expression alone cannot
explain the lower bilirubin levels in insulin resistant and MetS
subjects [2]. Although little explored, insulin could also affect
bilirubin metabolism, since insulin deficiency may result in
enhanced UDP-glucuronyltransferase activity and bilirubin excre-
tion [36]. Further study is required to more precisely delineate the
mechanisms responsible for the alleged effects of thyroid functional
status on bilirubin metabolism. Moreover, it remains to be
established why bilirubin was related to free T4 (and in univariable
analysis also to free T3) but not to the TSH level, extending our
previous report showing relationships of plasma lipids with free
thyroid hormone levels rather than with TSH [13].
Several other methodological issues and limitations of the
present study warrant consideration. First, euthyroidism was
strictly defined as levels of free T4, free T3 and TSH within the
assay-specific reference range as provided by the manufacturer.
We also excluded subjects with positive anti-thyroid peroxidase
auto-antibodies. This was done to reduce possible bias in the
relationship of free thyroid hormone levels with TSH in subjects
with very early stages of autoimmune thyroid dysfunction as much
as possible. Second, we performed a cross-sectional study. Thus,
cause-effect relationships cannot be established with certainty.
However, bilirubin has been shown not to influence the set-point
of the pituitary-thyroid axis [37], strongly suggesting that low
bilirubin levels by themselves are unlikely to lower thyroid
function. Third, statin treatment has been reported to decrease
bilirubin levels [38], and to increase plasma glucose [39], whereas
ACEi or ARB’s are likely to inhibit oxidative stress [40] and to
improve insulin sensitivity [41]. In primary analyses, we did not
exclude subjects using lipid lowering drugs or individuals using
ACEi or ARB’s. Instead, we carried out a secondary analysis after
exclusion of subjects using these medications. This secondary
analysis showed an essentially unaltered relationship of bilirubin
with free T4 and a similar interaction of free T4 with HOMA-IR
on bilirubin.
In conclusion, the current study shows an independent
relationship of low bilirubin with low free T4 in euthyroid subjects.
Low normal free T4 may particularly confer low bilirubin in more
insulin resistant individuals. Since bilirubin is a potent endogenous
anti-oxidant, it is plausible to speculate that low normal thyroid
functional status could enhance atherosclerosis susceptibility in the
context of insulin resistance.
Supporting Information
Table S1 Multivariable linear regression models dem-
onstrating interactions of free T4 with metabolic syn-
drome components on bilirubin.
(DOCX)
Table 3. Multivariable linear regression models demonstrating the interaction between free T4 and insulin resistance on bilirubin.
Model 1 Model 2 Model 3
b P-value b P-value b P-value
Age (years) 20.030 0.196 20.031 0.189 20.004 0.864
Sex (men/women) 20.250 ,0.001 20.251 ,0.001 20.213 ,0.001
Free T4 (pmol/L) 0.069 0.002 0.072 0.002 0.084 ,0.001
HOMA-IR 20.134 ,0.001 20.134 ,0.001 20.158 ,0.001
Free T4*HOMA-IR 0.043 0.056 0.044 0.044
Current smoker (yes/no) 20.184 ,0.001
Alcohol intake ($10 gram/day) 0.026 0.250
Total cholesterol (mmol/L) 20.101 ,0.001
AST (U/L) 0.097 0.003
ALT (U/L) 0.015 0.675
HOMA-IR, Homeostasis model assessment-insulin resistance; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; b, standardized regression coefficient.
Bilirubin, HOMA-IR, AST and ALT were log transformed.
doi:10.1371/journal.pone.0090886.t003
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